{"id":"ribavirin-r","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":null,"effect":"Teratogenicity/embryocidal effects"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-10","effect":"Dyspnea"},{"rate":"10-15","effect":"Insomnia"}]},"_chembl":null,"_dailymed":{"setId":"adf16e64-345f-469a-b987-3fbdd17e0ac2","title":"VIRAZOLE (RIBAVIRIN) POWDER, FOR SOLUTION [BAUSCH HEALTH US, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is converted intracellularly to its active triphosphate form, which depletes cellular GTP pools and directly inhibits viral RNA-dependent RNA polymerase. This dual mechanism reduces both the availability of nucleotides for viral replication and the catalytic efficiency of viral polymerases, thereby suppressing viral protein synthesis and replication across multiple RNA viruses.","oneSentence":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:45:49.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C (in combination with interferon-alpha or direct-acting antivirals)"},{"name":"Severe respiratory syncytial virus (RSV) infection"},{"name":"Lassa fever"},{"name":"Hantavirus pulmonary syndrome"}]},"trialDetails":[{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT02219490","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-30","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":1596},{"nctId":"NCT02308241","phase":"NA","title":"Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-02","conditions":"Human Papillomavirus (HPV)-Related Malignancies, Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies","enrollment":12},{"nctId":"NCT05532306","phase":"PHASE1","title":"Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2020-10-11","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT02167945","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":615},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT02194998","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-09-16","conditions":"HIV Infections, Hepatitis C","enrollment":46},{"nctId":"NCT01715415","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":395},{"nctId":"NCT02247401","phase":"PHASE3","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-04","conditions":"HCV, Hepatitis C Infection, Genotype 4","enrollment":160},{"nctId":"NCT01685203","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Hepatitis C, Chronic","enrollment":316},{"nctId":"NCT02023112","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Hepatitis C Virus","enrollment":171},{"nctId":"NCT02582632","phase":"PHASE3","title":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-24","conditions":"Hepatitis C Infection, Hepatitis C Virus","enrollment":166},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT01716585","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":636},{"nctId":"NCT01674725","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Chronic Hepatitis C Infection","enrollment":187},{"nctId":"NCT01767116","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Chronic Hepatitis C Infection","enrollment":419},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT01704755","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10","conditions":"Chronic Hepatitis C Infection, Compensated Cirrhosis","enrollment":381},{"nctId":"NCT01833533","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":305},{"nctId":"NCT02292719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-19","conditions":"Chronic Hepatitis C Virus Infection","enrollment":70},{"nctId":"NCT03020082","phase":"PHASE3","title":"Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":141},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT02461745","phase":"PHASE4","title":"Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2015-06","conditions":"Hepatitis C, Chronic","enrollment":200},{"nctId":"NCT03020095","phase":"PHASE2","title":"Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2015-08","conditions":"Chronic Hepatitis C","enrollment":38},{"nctId":"NCT03362814","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2017-07-01","conditions":"HCV","enrollment":425},{"nctId":"NCT04391985","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":113},{"nctId":"NCT04378608","phase":"PHASE1, PHASE2","title":"Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-01-05","conditions":"Hepatitis C Virus Infection","enrollment":100},{"nctId":"NCT03499639","phase":"PHASE4","title":"Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-05-01","conditions":"End-stage Renal Disease, HCV Coinfection","enrollment":110},{"nctId":"NCT02803138","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-07","conditions":"Chronic Hepatitis C","enrollment":256},{"nctId":"NCT02615145","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-03","conditions":"Chronic Hepatitis C","enrollment":472},{"nctId":"NCT02851069","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-23","conditions":"Chronic Hepatitis C","enrollment":66},{"nctId":"NCT02636608","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-27","conditions":"Chronic Hepatitis C","enrollment":244},{"nctId":"NCT02618928","phase":"","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-15","conditions":"Chronic Hepatitis C","enrollment":735},{"nctId":"NCT02582658","phase":"","title":"Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-06","conditions":"Chronic Hepatitis C","enrollment":173},{"nctId":"NCT02817594","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-20","conditions":"Chronic Hepatitis C","enrollment":51},{"nctId":"NCT02582671","phase":"","title":"The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-05","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT02581189","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-13","conditions":"Chronic Hepatitis C","enrollment":565},{"nctId":"NCT02725866","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-05","conditions":"Chronic Hepatitis C","enrollment":216},{"nctId":"NCT03053180","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Chronic Hepatitis C","enrollment":60},{"nctId":"NCT02807402","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-14","conditions":"Chronic Hepatitis C","enrollment":522},{"nctId":"NCT02798315","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-25","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02669940","phase":"","title":"Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-15","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":158},{"nctId":"NCT03710252","phase":"PHASE4","title":"A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","status":"COMPLETED","sponsor":"American Research Corporation","startDate":"2016-03","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT02640547","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Chronic Hepatitis C","enrollment":394},{"nctId":"NCT02517528","phase":"PHASE3","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07-20","conditions":"Chronic Hepatitis C Virus (HCV)","enrollment":104},{"nctId":"NCT02105454","phase":"PHASE2","title":"Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Hepatitis C Virus","enrollment":79},{"nctId":"NCT03020004","phase":"PHASE2","title":"Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2016-01","conditions":"Chronic Hepatitis C","enrollment":70},{"nctId":"NCT01563536","phase":"PHASE2","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02","conditions":"Chronic Hepatitis C Infection","enrollment":12},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT01911845","phase":"PHASE2","title":"An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04","conditions":"Chronic Hepatitis C Infection, Chronic Hepatitis C","enrollment":38},{"nctId":"NCT02068222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus","enrollment":10},{"nctId":"NCT02356562","phase":"PHASE2","title":"A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-02-03","conditions":"Chronic Hepatitis C Infection","enrollment":29},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3},{"nctId":"NCT02207088","phase":"PHASE3","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-23","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":68},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":"Chronic Hepatitis C Infection","enrollment":129},{"nctId":"NCT02493855","phase":"PHASE2","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":46},{"nctId":"NCT00302081","phase":"PHASE3","title":"Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08","conditions":"Hepatitis C, Chronic","enrollment":696},{"nctId":"NCT00049842","phase":"PHASE3","title":"Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10","conditions":"Chronic Hepatitis C, Liver Fibrosis","enrollment":540},{"nctId":"NCT02399345","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03","conditions":"Chronic Hepatitis C Virus (HCV Infection Genotype 1)","enrollment":10},{"nctId":"NCT01278134","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":170},{"nctId":"NCT01458535","phase":"PHASE2","title":"A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09","conditions":"Hepatitis C Virus","enrollment":61},{"nctId":"NCT02216422","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":36},{"nctId":"NCT01528735","phase":"PHASE2","title":"This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":398},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01464827","phase":"PHASE2","title":"ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1","enrollment":580},{"nctId":"NCT00892697","phase":"PHASE2","title":"Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-05","conditions":"Hepatitis C","enrollment":15},{"nctId":"NCT01467479","phase":"PHASE3","title":"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-12","conditions":"Hepatitis C","enrollment":185},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT01306617","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-02","conditions":"Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus","enrollment":50},{"nctId":"NCT01221298","phase":"PHASE2","title":"A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":11},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT01241760","phase":"PHASE3","title":"VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2010-12","conditions":"Genotype 1 Chronic Hepatitis C, Treatment Naive","enrollment":744},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT02027493","phase":"NA","title":"Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":46},{"nctId":"NCT01025596","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)","status":"COMPLETED","sponsor":"Cytheris SA","startDate":"2007-05","conditions":"Hepatitis C","enrollment":10},{"nctId":"NCT01024894","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy","status":"UNKNOWN","sponsor":"Cytheris SA","startDate":"2009-01","conditions":"Hepatitis C","enrollment":15},{"nctId":"NCT01025297","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone","status":"UNKNOWN","sponsor":"Cytheris SA","startDate":"2008-07","conditions":"Hepatitis C","enrollment":18},{"nctId":"NCT00437684","phase":"PHASE3","title":"Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2007-02","conditions":"HIV Infections, Hepatitis C","enrollment":50},{"nctId":"NCT00437476","phase":"PHASE3","title":"Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2007-02","conditions":"HIV Infections, Hepatitis C","enrollment":60},{"nctId":"NCT00299936","phase":"PHASE3","title":"Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"","conditions":"Chronic Hepatitis C","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":607,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["COPEGUS"],"phase":"marketed","status":"active","brandName":"Ribavirin (R)","genericName":"Ribavirin (R)","companyName":"Tibotec Pharmaceuticals, Ireland","companyId":"tibotec-pharmaceuticals-ireland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity. Used for Chronic hepatitis C (in combination with interferon-alpha or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Lassa fever.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}